These Analysts Slash Their Forecasts On Abivax Following H1 Results
Abivax missed EPS estimates but beat sales in H1; shares dipped. Wedbush and Truist cut price targets to $118 and $151.
Share
Why It Matters
Abivax made more money than expected but earned less per share than analysts thought. This makes some experts less hopeful about the stock's price going forward.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.